What is AllCells?
AllCells is a specialized provider of high-quality human primary cells and whole tissue products, catering to medical, scientific, and academic research globally. The company offers a comprehensive catalog of cryopreserved and fresh cells, including leukopaks, bone marrow, and cord blood, designed to meet the rigorous demands of life science researchers and bio-manufacturing organizations. With a strong emphasis on donor management and custom cell isolation services, AllCells ensures the timely delivery of compliant products, supporting the advancement of complex therapies, particularly within the cell and gene therapy domain.
How much funding has AllCells raised?
AllCells has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for AllCells?
The recent major strategic investment signals a period of accelerated growth and development for AllCells. This capital infusion is expected to bolster the company's capabilities in cell and gene therapy research support, potentially expanding its product lines, enhancing its donor network, and scaling its bio-manufacturing operations. The company's focus on GMP compliance and custom isolation services positions it to capitalize on the increasing demand for reliable, high-quality biological materials in cutting-edge therapeutic development.
See full AllCells company page
